IQR Group Pty Ltd - Resultats de la cerca

Nova Zelanda - anglès - Medsafe (Medicines Safety Authority)

eloctate

pharmacy retailing (nz) ltd t/a healthcare logistics - efmoroctocog alfa 2000 [iu]; - powder for infusion - 2000 iu - active: efmoroctocog alfa 2000 [iu] excipient: calcium chloride dihydrate histidine polysorbate 20 sodium chloride sucrose water for injection - eloctate is a long-acting antihaemophilic factor (recombinant) indicated in adults and children with haemophilia a (congenital factor viii deficiency) for: · control and prevention of bleeding episodes · routine prophylaxis to prevent or reduce the frequency of bleeding episodes · perioperative management (surgical prophylaxis). eloctate does not contain von willebrand factor, and therefore is not indicated in patients with von willebrand's disease.

Nova Zelanda - anglès - Medsafe (Medicines Safety Authority)

eloctate

pharmacy retailing (nz) ltd t/a healthcare logistics - efmoroctocog alfa 250 [iu]; - powder for infusion - 250 iu - active: efmoroctocog alfa 250 [iu] excipient: calcium chloride dihydrate histidine polysorbate 20 sodium chloride sucrose water for injection - eloctate is a long-acting antihaemophilic factor (recombinant) indicated in adults and children with haemophilia a (congenital factor viii deficiency) for: · control and prevention of bleeding episodes · routine prophylaxis to prevent or reduce the frequency of bleeding episodes · perioperative management (surgical prophylaxis). eloctate does not contain von willebrand factor, and therefore is not indicated in patients with von willebrand's disease.

Nova Zelanda - anglès - Medsafe (Medicines Safety Authority)

eloctate

pharmacy retailing (nz) ltd t/a healthcare logistics - efmoroctocog alfa 3000 [iu]; - powder for infusion - 3000 iu - active: efmoroctocog alfa 3000 [iu] excipient: calcium chloride dihydrate histidine polysorbate 20 sodium chloride sucrose water for injection - eloctate is a long-acting antihaemophilic factor (recombinant) indicated in adults and children with haemophilia a (congenital factor viii deficiency) for: · control and prevention of bleeding episodes · routine prophylaxis to prevent or reduce the frequency of bleeding episodes · perioperative management (surgical prophylaxis). eloctate does not contain von willebrand factor, and therefore is not indicated in patients with von willebrand's disease.

Nova Zelanda - anglès - Medsafe (Medicines Safety Authority)

eloctate

pharmacy retailing (nz) ltd t/a healthcare logistics - efmoroctocog alfa 500 [iu]; - powder for infusion - 500 iu - active: efmoroctocog alfa 500 [iu] excipient: calcium chloride dihydrate histidine polysorbate 20 sodium chloride sucrose water for injection - eloctate is a long-acting antihaemophilic factor (recombinant) indicated in adults and children with haemophilia a (congenital factor viii deficiency) for: · control and prevention of bleeding episodes · routine prophylaxis to prevent or reduce the frequency of bleeding episodes · perioperative management (surgical prophylaxis). eloctate does not contain von willebrand factor, and therefore is not indicated in patients with von willebrand's disease.

Nova Zelanda - anglès - Medsafe (Medicines Safety Authority)

eloctate

pharmacy retailing (nz) ltd t/a healthcare logistics - efmoroctocog alfa 750 [iu]; - powder for infusion - 750 iu - active: efmoroctocog alfa 750 [iu] excipient: calcium chloride dihydrate histidine polysorbate 20 sodium chloride sucrose water for injection - eloctate is a long-acting antihaemophilic factor (recombinant) indicated in adults and children with haemophilia a (congenital factor viii deficiency) for: · control and prevention of bleeding episodes · routine prophylaxis to prevent or reduce the frequency of bleeding episodes · perioperative management (surgical prophylaxis). eloctate does not contain von willebrand factor, and therefore is not indicated in patients with von willebrand's disease.